Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 7Phase 3 2Phase NA 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia 23Lymphoma 21Leukemia, Myeloid, Acute 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Myelodysplastic Syndromes 13Multiple Myeloma 13Breast Neoplasms 13Ovarian Neoplasms 11Lymphoma, Follicular 10Lymphoma, Mantle-Cell 9Leukemia, Lymphocytic, Chronic, B-Cell 9Leukemia, Biphenotypic, Acute 9Hodgkin Disease 9Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 8Sarcoma 7Waldenstrom Macroglobulinemia 6Burkitt Lymphoma 6Testicular Neoplasms 5Testicular Germ Cell Tumor 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Myelomonocytic, Chronic 5Carcinoma, Ovarian Epithelial 5Blast Crisis 5Myeloproliferative Disorders 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Congenital Abnormalities 4Central Nervous System Neoplasms 4

Interventions

pembrolizumab 74Nivolumab 53Ipilimumab 42Cyclophosphamide 31Interleukin-2 24aldesleukin 23Temozolomide 17fludarabine 15Biopsy 11trametinib 10dabrafenib 10fludarabine phosphate 9spartalizumab 8Paclitaxel 8Dacarbazine 8sargramostim 7cemiplimab 7binimetinib 7Cisplatin 7Bevacizumab 7poly ICLC 6lenvatinib 6epacadostat 6Radiotherapy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5encorafenib 5atezolizumab 5Vemurafenib 5Specimen Handling 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Melanoma × Filgrastim × Clear all
NCT00062036 2017-07-02

Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
33 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡